Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Neo Kuma Ventures is the UK's first investment fund focused solely on psychedelic healthcare, founded in 2020 by Clara Burtenshaw, Sean McLintock, and Nick David. The firm is headquartered in London and launched its fund in December 2020, raising over £10 million within the first five months, exceeding initial fundraising targets. Neo Kuma Ventures aims to support early-stage companies that are pioneering innovative solutions in mental health through psychedelic therapies.
As of 2023, Neo Kuma Ventures has made 14 investments, demonstrating a strong commitment to the psychedelic healthcare sector. The firm has a global investment approach, with a particular emphasis on European markets. Their portfolio includes notable companies that are advancing clinical research and redefining patient care standards. The firm’s expertise in clinical research and pharmaceutical backgrounds allows it to provide strategic guidance and support to its portfolio companies.
Neo Kuma Ventures invests in early-stage companies within the psychedelic healthcare sector, targeting pre-seed to Series A stages. The firm focuses on global markets, particularly in Europe, and invests in various categories including psychedelic compounds, clinics and care delivery, and digital therapeutics and platforms. The average check size ranges from £150,000 to £1 million, allowing for flexibility in supporting diverse startups.
The firm seeks to back pharmaceutical-credentialed companies guided by clinical science, emphasizing the importance of innovative solutions in mental health. Neo Kuma Ventures is dedicated to advancing clinical research and redefining patient care standards through its investments. They look for founders who are passionate about solving problems and improving lives, and they provide support in navigating regulatory landscapes to help accelerate growth.
Neo Kuma Ventures has built a diverse portfolio of 14 companies, focusing on the psychedelic healthcare sector. Notable portfolio companies include:
Among these, Bright Minds Biosciences and ATAI Life Sciences have achieved notable exits, with Bright Minds listing on the Canadian Securities Exchange.
Clara Burtenshaw: Co-Founder and Investor at Neo Kuma Ventures, Clara has a background in pharmaceuticals and serves as a key spokesperson for the firm. She emphasizes the importance of backing companies guided by science.
Sean McLintock: Co-Founder and Investor, Sean brings extensive experience in venture capital and a strong focus on the psychedelic healthcare sector.
Nick David: Co-Founder, Nick has been instrumental in establishing Neo Kuma Ventures and has a keen interest in innovative healthcare solutions.
Dr. Peter Crane: Venture Partner, Dr. Crane has a background in clinical research and provides valuable insights into the healthcare landscape.
Dr. Willem Hendrik Gispen: Medical Biologist and Neuroscientist, Dr. Gispen contributes expertise in the scientific aspects of psychedelic therapies.
Isabel Fox: Advisory Board member, Isabel brings a wealth of experience in healthcare investments.
Lomax Ward: Advisory Board member, Lomax has a strong background in venture capital and healthcare.
Christina Sass: Advisory Board member, Christina provides strategic guidance and insights into the healthcare market.
To pitch to Neo Kuma Ventures, startups should visit their website at neokuma.co. It is recommended to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. The firm prefers pitches that demonstrate a strong scientific foundation and a clear path to addressing mental health issues.
Response times may vary, but founders should expect to hear back within a few weeks. Warm introductions are beneficial, as they can enhance the likelihood of a favorable review.
As of March 2023, Neo Kuma Ventures has made a total of 14 investments since its inception in 2020. The firm has seen notable success with three of its initial portfolio companies going public in 2021, including Bright Minds Biosciences, which listed on the Canadian Securities Exchange.
In addition to its investment activities, Neo Kuma Ventures continues to expand its portfolio, focusing on companies that are pioneering innovative solutions in mental health through psychedelic therapies. The firm remains committed to advancing clinical research and redefining patient care standards.
What are Neo Kuma Ventures' investment criteria?
Neo Kuma Ventures focuses on early-stage companies within the psychedelic healthcare sector, specifically targeting pre-seed to Series A stages. They invest in companies that are pioneering innovative solutions in mental health through psychedelic therapies.
How can startups apply or pitch to Neo Kuma Ventures?
Startups can pitch to Neo Kuma Ventures through their website at neokuma.co. It is advisable to include a detailed deck that outlines the business model, market opportunity, and team background.
What makes Neo Kuma Ventures different from other investors?
Neo Kuma Ventures is distinguished by its exclusive focus on psychedelic healthcare, making it the UK's first fund dedicated to this sector. Their expertise in clinical research and pharmaceutical backgrounds allows them to provide unique insights and support to portfolio companies.
What is the geographic scope of Neo Kuma Ventures?
The firm has a global investment approach, with a particular emphasis on European markets. They also consider opportunities in the United States, especially in the psychedelic healthcare space.
What is the typical check size for investments?
Neo Kuma Ventures typically invests between £150,000 and £1 million in their portfolio companies, allowing for flexibility in supporting various stages of growth.
What kind of post-investment involvement does Neo Kuma Ventures have?
Neo Kuma Ventures provides strategic guidance, access to a network of industry professionals, and support in navigating regulatory landscapes, helping portfolio companies accelerate their growth and achieve successful outcomes.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.